[Improvement of host-immunity by adjuvant therapy with juzen-taiho-to for patients with brain tumors].
T cell subset, natural killer (NK) cell activity and tumor necrosis factor alpha (TNF-alpha) productivity of lymphocytes in the peripheral blood were investigated in order to study host-immunity before and after administration of Juzentaiho-to (TJ-48) with or without Interferon-beta (INF-beta) for 29 patients with brain tumors (15 cases of gliomas and 14 cases of non-glial tumors). "A" group was given TJ-48 (7.5 g/day, p.o.) with INF-beta 300 million IU/1-2 weeks after initial treatment, and "B" group was treated by only TJ-48. % values of helper T cells (CD4+, CD45RA-), cytotoxic T cells (CD8+, 11b-), suppressor T cells (CD8+ +. 11b+) and NK activity were calculated with two color flowcytometry before and at 1 month, 2 months and 3 months after the administration of TJ-48. TNF-alpha productivity of lymphocytes was examined by the ELISA method at the same time. Suppressor T cells decreased significantly after 2 months following administration of JT-48 in 16 of 17 cases in both A and B group. After administration of TJ-48, helper T cells tended to increase slightly, but cytotoxic T cells and NK activity did not change. TNF-alpha productivity was measured in 8 cases of gliomas and increased to levels higher than they were before administration of TJ-48 in all of the cases which were examined more than 2 months after treatment. Adjuvant therapy with TJ-48 in both A and B group improved the host-immunity of the patients with brain tumors. It was concluded that it was useful as an assistant treatment for brain tumors.
Miyagami
Mitsusuke
M
Department of Neurological Surgery, Nihon University School of Medicine, Japan.
Katayama
Yoichi
Y
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000276:immunology*; D017024:Chemotherapy, Adjuvant; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005910:Glioma / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D016899:Interferon-beta / Q000008:administration & dosage; D007694:Killer Cells, Natural; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D016176:T-Lymphocyte Subsets; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis
D000970:Antineoplastic Agents; D004365:Drugs, Chinese Herbal; D014409:Tumor Necrosis Factor-alpha; C063587:juzentaihoto; D016899:Interferon-beta